ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study.
James I GellerJoseph G PresseyMalcolm A SmithRachel A KudgusMariana CajaibaJoel M ReidDavid HallDonald A BarkauskasStephen D VossSteve Y ChoStacey L BergJeffrey S DomeElizabeth FoxBrenda J WeigelPublished in: Cancer (2020)
Lorvotuzumab mertansine (110 mg/m2 ) is tolerated in children at the adult recommended phase 2 dose; clinical activity is limited.